Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Phase-II-Studie zu Safusidenib-Erbumin bei chemotherapie- und radiotherapienaiven IDH1-mutierten WHO-Grad-2-Gliomen
Neuro-Oncology · 01.03.2026 · 28 (3) · 717-727
DOI: 10.1093/neuonc/noaf258 ↗Auf einen Blick
In 27 Patient:innen mit IDH1-mutierten WHO-Grad-2-Gliomen lag die bestätigte objektive Ansprechrate bei 44,4 %. Das mediane progressionsfreie Überleben wurde nicht erreicht.
Fragestellung
Wirksamkeit und Sicherheit von Safusidenib-Erbumin bei chemotherapie- und radiotherapienaiven IDH1-mutierten WHO-Grad-2-Gliomen?
Methode
Multizentrische, offene, einarmige Phase-II-Studie bei 27 Patient:innen (NCT04458272).
Ergebnisse
Bestätigte objektive Ansprechrate 44,4 %. Medianes progressionsfreies Überleben nicht erreicht; ereignisfreie Wahrscheinlichkeit nach 24 Monaten 87,9 %. Häufige TEAEs: Alopezie 59,3 %, Arthralgie 55,6 %, Hauthyperpigmentierung 48,1 %, ALT erhöht 40,7 %.
Schlussfolgerung der Autor:innen
Safusidenib-Erbumin ist laut Autor:innen eine potenzielle Behandlungsoption für Patient:innen mit chemotherapie- und radiotherapienaiven IDH1-mutierten WHO-Grad-2-Gliomen.
Kernaussagen
- Bestätigte objektive Ansprechrate: 44,4 %
- Medianes PFS nicht erreicht; 24-Monats-ereignisfrei 87,9 %
- Häufigste TEAEs: Alopezie, Arthralgie, Hauthyperpigmentierung, ALT-Anstieg
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 08.11.2025. Verfasst von Yoshiki Arakawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto (Y.A.). Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Co., Ltd..
Themen: Onkologische Pflege
Abstract (Originalsprache)
AbstractAbstract Background Gliomas are primary brain tumors arising from glial cells. WHO grade 2 gliomas are initially managed with surgery for diagnosis and tumor reduction. However, complete resection is difficult due to their infiltrative growth into the normal brain and the need to preserve brain function. Current treatment options for WHO grade 2 gliomas are limited. Isocitrate dehydrogenase 1 (IDH1) mutations are frequently observed in WHO grade 2 gliomas. Safusidenib erbumine is a selective inhibitor of mutant IDH1 with substantial blood-brain barrier penetration. This study aimed to investigate the efficacy and safety of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 gliomas.
Methods
This phase II study implemented a multicenter, open-label, single-arm design and evaluated the efficacy and safety of safusidenib erbumine in 27 patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 gliomas (NCT04458272).
Results
The confirmed objective response rate according to the Response Assessment in Neuro-Oncology criteria for WHO grade 2 gliomas was 44.4%. Median progression-free survival was not reached, with an event-free probability of 87.9% at 24 months. The frequently reported treatment-emergent adverse events (TEAEs) by Medical Dictionary for Regulatory Activities Preferred Terms (reported in ≥40%) were alopecia (59.3%), arthralgia (55.6%), skin hyperpigmentation (48.1%), and alanine aminotransferase increased (40.7%). Treatment-emergent adverse events were characterized as mostly grade 1 or 2. The incidence of treatment-related grade ≥3 TEAEs was 18.5%.
Conclusions
Safusidenib erbumine is a potential treatment option for patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto (Y.A.).
- Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya (R.S., K.Mo.).
- Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka (Y.Kan.).
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka (K.Mi.).
- Department of Neurosurgery, Tokyo Women's Medical University, Tokyo (S.K.).
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo (Y.N.).
ORCID-Profile: Yoshiki Arakawa, Ryuta Saito, Yoshitaka Narita, Fumiyuki Yamasaki, Masayuki Kanamori, Motoo Nagane
Förderung
- Daiichi Sankyo Co., Ltd.
Zitieren
APA
Arakawa, Y., Saito, R., Kanemura, Y., Mishima, K., Koriyama, S., Narita, Y., Kumabe, T., Motomura, K., Sugiyama, K., Yamasaki, F., Mukasa, A., Kanamori, M., Kuga, D., Nagane, M., Kakurai, Y., Isobe, K., & Nakamura, H. (2026). Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. Neuro-Oncology, 28(3), 717-727. https://doi.org/10.1093/neuonc/noaf258
Vancouver
Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, et al. Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. Neuro-Oncology. 2026;28(3):717-727. doi:10.1093/neuonc/noaf258
BibTeX
@article{Arakawa2026,
author = {Arakawa, Yoshiki and Saito, Ryuta and Kanemura, Yonehiro and Mishima, Kazuhiko and Koriyama, Shunichi and Narita, Yoshitaka and Kumabe, Toshihiro and Motomura, Kazuya and Sugiyama, Kazuhiko and Yamasaki, Fumiyuki and Mukasa, Akitake and Kanamori, Masayuki and Kuga, Daisuke and Nagane, Motoo and Kakurai, Yasuyuki and Isobe, Koji and Nakamura, Hideo},
title = {Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {3},
pages = {717--727},
doi = {10.1093/neuonc/noaf258}
}
EUVIMED